Free Trial
NASDAQ:VYNE

VYNE Therapeutics Q1 2025 Earnings Report

VYNE Therapeutics logo
$1.33 -0.08 (-5.67%)
As of 04:00 PM Eastern

VYNE Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.29
Beat/Miss
N/A
One Year Ago EPS
N/A

VYNE Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.05 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

VYNE Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Friday, May 9, 2025
Conference Call Time
12:30PM ET

Conference Call Resources

VYNE Therapeutics Earnings Headlines

New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
See More VYNE Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like VYNE Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VYNE Therapeutics and other key companies, straight to your email.

About VYNE Therapeutics

VYNE Therapeutics (NASDAQ:VYNE), a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

View VYNE Therapeutics Profile

More Earnings Resources from MarketBeat